NRXS
NeurAxis, Inc. AMEX$8.30
Mkt Cap $95.5M
52w Low $1.94
98.5% of range
52w High $8.40
50d MA $6.83
200d MA $4.11
P/E (TTM)
-8.5x
EV/EBITDA
-4.8x
P/B
21.6x
Debt/Equity
0.1x
ROE
-229.5%
P/FCF
-6.4x
RSI (14)
—
ATR (14)
—
Beta
1.89
50d MA
$6.83
200d MA
$4.11
Avg Volume
164.1K
About
NeurAxis, Inc. operates as a neuromodulation therapy device company in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome healthcare companies primarily hospitals and clinics. The company was formerly known as Innovative Health Solut…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 19, 2026 | AMC | -0.21 | -0.17 | +20.9% | 7.16 | +1.3% | +6.4% | +2.1% | -1.5% | +4.9% | -2.2% | -2.2% | — |
| Nov 10, 2025 | AMC | — | -0.24 | — | 2.56 | -4.7% | -5.9% | +1.6% | -8.2% | -8.6% | -9.8% | +7.8% | — |
| Aug 12, 2025 | AMC | — | -0.22 | — | 2.49 | -0.4% | -1.2% | -4.8% | -3.2% | -0.4% | -5.2% | -2.8% | — |
| May 12, 2025 | AMC | -0.24 | -0.31 | -29.2% | 2.32 | -2.6% | -0.9% | -2.2% | +1.7% | -3.0% | -2.2% | +7.3% | — |
| Mar 20, 2025 | AMC | — | -0.21 | — | 2.27 | +2.6% | +1.8% | -4.4% | -3.5% | -5.3% | -6.2% | -21.1% | — |
| Nov 12, 2024 | AMC | — | -0.25 | — | 3.16 | -4.1% | +0.0% | +3.5% | -0.3% | -1.9% | +2.8% | -16.5% | — |
| Aug 9, 2024 | AMC | — | -0.42 | — | 3.11 | +1.9% | +1.9% | +2.6% | +1.2% | +0.8% | +2.3% | +1.0% | — |
| May 20, 2024 | AMC | — | -0.32 | — | 2.97 | +1.0% | +2.7% | -2.0% | +2.0% | +6.4% | +6.4% | -9.1% | — |
| Apr 16, 2024 | AMC | — | 0.29 | — | 3.13 | +0.2% | -0.9% | +3.9% | +0.4% | +1.5% | -9.8% | -1.2% | — |
| Nov 20, 2023 | AMC | -0.17 | -1.06 | -523.5% | 2.34 | +3.2% | +3.0% | +13.7% | +28.2% | +30.3% | +28.2% | -9.8% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 20 | Craig-Hallum | Maintains | Buy → Buy | — | $7.16 | $7.25 | +1.3% | +6.4% | +2.1% | -1.5% | +4.9% | -2.2% |
| Dec 22 | Craig-Hallum | Maintains | Buy → Buy | — | $3.22 | $3.26 | +1.2% | +25.2% | +8.1% | +18.6% | +21.7% | +30.4% |
Recent Filings
8-K · 8.01
!! High
Neuraxis, Inc. -- 8-K 8.01: Material Event / Announcement
Neuraxis established a $6.27 million at-the-market offering with Craig-Hallum Capital Group and has sold 1,125,281 shares through April 20, 2026.
Apr 22
8-K
Neuraxis, Inc. -- 8-K Filing
Neuraxis reports preliminary Q1 2026 financial results that may require material adjustments pending final accounting review and auditor verification.
Apr 21
Data updated apr 26, 2026 3:48pm
· Source: massive.com